Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trialNathan Fowler, Catherine Thiéblemont, Julio C. Chávez et al.|Nature Medicine|2021Cited by 523
Is there a role for antigen selection in mantle cell lymphoma? Immunogenetic support from a series of 807 casesAnastasia Hadzidimitriou, Κώστας Σταματόπουλος, Andreas Agathangelidis et al.|Blood|2011Cited by 178
Phospho-specific flow cytometry identifies aberrant signaling in indolent B-cell lymphomaEgil Støre Blix, Arne Kolstad|BMC Cancer|2012Cited by 32
138 | PHASE 2 ELARA TRIAL 4‐YEAR UPDATE: CLINICAL OUTCOMES OF TISAGENLECLEUCEL IN PATIENTS (PTS) WITH HIGH‐RISK RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA (R/R FL)Catherine Thiéblemont, Nathan Fowler, M. Dreyling et al.|Hematological Oncology|2025Cited by 1